#2 Bronchiolitis: 2019 RSV Update

Guest: Miguel Knochel, MD, FAAP

February 2019

 

SUBSCRIBE:

Listen on Google Play Music

Show Notes

Disclosures

No commercial support is associated with this CME activity.

Disclosure of Financial Relationships and Resolution of Conflicts of Interest for AAP CME Activities

The AAP CME/CPD program develops, maintains, and improves the competence, skills, and professional performance of pediatricians and pediatric healthcare professionals by providing quality, relevant, accessible, and effective educational experiences that address gaps in professional practice.  The AAP CME/CPD program strives to meet the educational needs of pediatricians and pediatric healthcare professionals and support their lifelong learning with a goal of improving care for children and families.  (AAP CME/CPD Program Mission Statement, May 2015)

 The AAP recognizes that there are a variety of financial relationships between individuals and commercial interests that require review to identify possible conflicts of interest in a CME activity. The “AAP Policy on Disclosure of Financial Relationships and Resolution of Conflicts of Interest for AAP CME Activities” is designed to ensure quality, objective, balanced, and scientifically rigorous AAP CME activities by identifying and resolving all potential conflicts of interest prior to the confirmation of service of those in a position to influence and/or control CME content. The AAP has taken steps to resolve any potential conflicts of interest.

All AAP CME activities will strictly adhere to the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support: Standards to Ensure the Independence of CME Activities. In accordance with these Standards, the following decisions will be made free of the control of a commercial interest: identification of CME needs, determination of educational objectives, selection and presentation of content, selection of all persons and organizations that will be in a position to control the content, selection of educational methods, and evaluation of the CME activity.

The purpose of this policy is to ensure all potential conflicts of interest are identified and mechanisms to resolve them prior to the CME activity are implemented in ways that are consistent with the public good. The AAP is committed to providing learners with commercially unbiased CME activities.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no relevant financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities.  Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content.  

* A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.   

Disclosure of Commercial Support for AAP CME Activities

No commercial support is associated with this CME activity.

Disclosure of Financial Relationships and Resolution of Conflicts of Interest for AAP CME Activities

The AAP CME/CPD program develops, maintains, and improves the competence, skills, and professional performance of pediatricians and pediatric healthcare professionals by providing quality, relevant, accessible, and effective educational experiences that address gaps in professional practice.  The AAP CME/CPD program strives to meet the educational needs of pediatricians and pediatric healthcare professionals and support their lifelong learning with a goal of improving care for children and families.  (AAP CME/CPD Program Mission Statement, May 2015)

 The AAP recognizes that there are a variety of financial relationships between individuals and commercial interests that require review to identify possible conflicts of interest in a CME activity. The “AAP Policy on Disclosure of Financial Relationships and Resolution of Conflicts of Interest for AAP CME Activities” is designed to ensure quality, objective, balanced, and scientifically rigorous AAP CME activities by identifying and resolving all potential conflicts of interest prior to the confirmation of service of those in a position to influence and/or control CME content. The AAP has taken steps to resolve any potential conflicts of interest.

All AAP CME activities will strictly adhere to the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support: Standards to Ensure the Independence of CME Activities. In accordance with these Standards, the following decisions will be made free of the control of a commercial interest: identification of CME needs, determination of educational objectives, selection and presentation of content, selection of all persons and organizations that will be in a position to control the content, selection of educational methods, and evaluation of the CME activity.

The purpose of this policy is to ensure all potential conflicts of interest are identified and mechanisms to resolve them prior to the CME activity are implemented in ways that are consistent with the public good. The AAP is committed to providing learners with commercially unbiased CME activities.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no relevant financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities.  Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content.  

* A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.   

 

Name Role

Relevant Financial Relationship

(Please indicate Yes or No)

Name of Commercial Interest(s)*

Please list name(s) of entity

AND

Nature of Relevant Financial Relationship(s)

(Please list: Research Grant, Speaker’s Bureau, Stock/Bonds excluding mutual funds, Consultant, Other – identify)

Disclosure of Off-Label (Unapproved)/Investigational Uses of Products
AAP CME faculty are required to disclose to the AAP and to learners when they plan to discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or “off-label” use of an approved device or pharmaceutical.

(Do intend to discuss or Do not intend to discuss)

Paul Wirkus Planner/Moderator NO NONE Do not intend to discuss
Miguel Knochel Faculty NO NONE Do not intend to discuss
Carolyn Reynolds Planner NO NONE Do not intend to discuss
Alison M. Barrington Planner NO NONE Do not intend to discuss
Brooke Hall Planner NO NONE Do not intend to discuss
Alisa Stoddard UTAAP Staff/COI Reviewer-Resolver NO NONE Do not intend to discuss

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Pediatrics (AAP) and the Utah Chapter of the AAP.  The American Academy of Pediatrics is accredited by the ACCME to provide continuing medical education for physicians.

The AAP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is acceptable for a maximum of 1.0 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.

PAs may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

 This program is accredited for 1.0 NAPNAP CE contact hours of which 0 contain pharmacology (Rx) content, (0 related to psychopharmacology) (0 related to controlled substances), per the National Association of Pediatric Nurse Practitioners (NAPNAP) Continuing Education Guidelines.

 MOC Statement:

Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 1.0 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

 If you do not successfully complete all components of the activity and evaluation assessment ABP MOC Part 2 Points will not be awarded.

 Please note: your completion data will be shared with the ABP through the ACCME PARS system within 30 days of successful completion.  This will include the name of the activity and provider; participant name; participant’s ABP ID number; participant’s DOB; date of completion of the activity; the PARS activity identifier; ABP MOC Part 2 credit statement and number of MOC points awarded.  If any questions or concerns please contact the activity manager alisa@aaputah.org.

Guest: Miguel Knochel, MD, FAAP

Quiz available after 4th episode airs, typically the fourth week of the month.

Virtual Curbside Podcast – Brohcniolitis
Dates valid for credit: November 1, 2019 – October 31, 2022

Claim for Credit

  • Learners who complete the activity are eligible for 1.0 AMA PRA Category 1 Credit TM.
  • Learners who complete all quiz questions, and who meet the 50% minimum passing score requirements, will be eligible for 1.0 MOC Part 2 points. 

Learning Objectives

After listening to these episodes listeners will…

  • learn what the recent literature on bronchiolitis shows about hypertonic saline, pulse oximetry, invasive suctioning high-flow nasal cannula.
  • discuss treatments and testing options to avoid doing routinely: CXR, viral testing systemic steriods, inhaled bronchodilators, invasive suctioning (NEW), continuous oximety (NEW).
  • discuss when to use High Flow Nasal Cannula, what flow rates to provide and when it is not helpful.

Time Stamps Episode 2-1

00:00 Introduction
02:46 Disclosures and Guest Introduction
05:23 RSV
07:22 Suctioning
11:00 How to prevent RSV
13:02 Inpatient management, hypertonic saline, pulse oximetry
17:49 Role of oxygen at home, discontinuation
20:47 Suctioning practices in the hospital
22:36 High Flow Nasal Cannula
23:58 Discharge
24:57 Escalation of care
28:50 Outro

Time Stamps Episode 2-2

00:00 Introduction
03:19 Chest X-ray, AAP recommendation
05:53 Viral testing
08:43 Steroids, bronchodialtor
13:09 Choosing Wisely: A Journey
15:10 AAP Change Package: Stewardship in Improving Bronchiolitis
15:45 Office based QI, PDSA cycles
18:34 Outro

Time Stamps Episode 2-3

00:00 Introduction
01:04 High Flow Nasal Cannula
09:27 RSV Vaccine
13:40 Palivizumab
16:33 Outro

Notes Episode 2-4

Dr. Knochel mistakenly mentioned Pediatric Grand Rounds would be March 8th.  The correct date is Thursday, March 7th at 8 am.  Link below.

Regarding flu swabbing guidelines:

Each lab may differ on acceptable specimens, even given these CDC guidelines.   Deep nasal (midturbinate) swab is apparently find for flu testing, but we’re not sure about other viruses.

For respiratory viral testing, Primary Children’s laboratory does not accept nasal swab + throat swab combo or deep nasal swab (yet), but we do take (with proper labeling & order) the following:

BAL, trach aspirate, Nasopharyngeal wash (in sterile saline), nasopharyngeal swab (UTM or M4 medium), nasopharyngeal aspirate (UTM or M4 medium), sputum sample (older kids who can hack up sputum or expectorate an induced sputum specimen).

Of course, a good question to ask before obtaining respiratory panel testing is:  “will this change my management?”  Usually for bronchiolitis the answer is no, unless you suspect influenza and will treat if positive, or if you think it’s pertussis.

Miguel Knochel MD

Acknowledgements

Written and Hosted by: Paul Wirkus, MD, FAAP
Administrator/Producer/Photographer: Alisa Stoddard, UTAAP Executive Director
Audio Engineer: Phil Wirkus
Music by: Phil Wirkus
Guest: Miguel Knochel, MD, FAAP
Special Thanks to Michelle Hofmann, MD, MPH, FAAP, Rob Willer, DO, FAAP and Eric Coon, MD, FAAP